* LeMaitre Vascular Inc LMAT.OQ LMAT.O is expected
to show a
rise in quarterly revenue when it reports results on August 1
for the period ending June 30 2024
* The Burlington Massachusetts-based company is expected to
report a 9.7% increase in revenue to $54.986 million from $50.12
million a year ago, according to the mean estimate from 9
analysts, based on LSEG data.The company's guidance on May 2
2024, for the period ended June 30, was for revenue between
53.70 million and 56.10 million.
* LSEG's mean analyst estimate for LeMaitre Vascular Inc is
for
earnings of 47 cents per share. The company's EPS guidance on
May 2 2024, for the period ended June 30, was about 0.47
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for LeMaitre
Vascular
Inc is $78.00, below its last closing price of $87.36.
The company's guidance on May 2 2024 for the period ended June
30 was for Earnings before Interest and Taxes of 12.9
million.The company's guidance on May 2 2024 for the period
ended June 30 was for gross profit margin of 68.6%.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 0.39 0.39 0.44 Beat 13.6
Dec. 31 2024 0.36 0.36 0.38 Beat 6.4
Sep. 30 2023 0.30 0.30 0.33 Beat 9.1
Jun. 30 2023 0.32 0.32 0.36 Beat 13.8
Mar. 0.26 0.25 0.27 Beat 7.4
31 2023
Dec. 31 2022 0.26 0.26 0.25 Missed
Jan. 1 0001 0.27 0.28 0.25 Missed -9.9
Jan. 1 0001 0.27 0.27 0.16 Missed -39.6
This summary was machine generated July 30 at 20:29 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)